NCT03860987View on ClinicalTrials.gov

Neoadjuvant Androgen Deprivation Therapy Combined With Enzalutamide and Abiraterone Using Multiparametric MRI and 18FDCFPyL PET/CT in Newly Diagnosed Prostate Cancer

PHASE2Active, not recruitingINTERVENTIONAL
Enrollment

12

Participants

Timeline

Start Date

April 30, 2019

Primary Completion Date

July 31, 2026

Study Completion Date

August 1, 2028

Conditions
Castrate Sensitive Prostate Cancer
Interventions
DRUG

goserelin

Goserelin will be administered SC at 10.8 mg every 12 weeks

DRUG

Enzalutamide

Enzalutamide will be given orally at 160mg once daily

DRUG

Abiraterone

Abiraterone will be taken orally at 1000 mg once daily

DRUG

18F-DCFPyL

18F-labeled agent that is a high affinity small molecule inhibitor of PSMA to detect prostate cancer via PET imaging

DRUG

Prednisone

Prednisone will be taken orally at 5mg twice a day for each dose, or 10 mg once a day. Doses should be taken about 12 or 24 hours apart

PROCEDURE

Radical Prostatectomy

Radical Prostatectomy

Trial Locations (1)

20892

National Institutes of Health Clinical Center, Bethesda

All Listed Sponsors
lead

National Cancer Institute (NCI)

NIH

NCT03860987 - Neoadjuvant Androgen Deprivation Therapy Combined With Enzalutamide and Abiraterone Using Multiparametric MRI and 18FDCFPyL PET/CT in Newly Diagnosed Prostate Cancer | Biotech Hunter | Biotech Hunter